modified vaccinia ankara virus-like particle human papillomavirus vaccine

A **modified vaccinia ankara virus-like particle human papillomavirus vaccine** is an investigational HPV immunotherapy based on a replication-deficient modified vaccinia Ankara vector engineered to express HPV antigens and, in some programs, to generate noninfectious virus-like particles in vivo. The intent is therapeutic rather than purely prophylactic: vaccination is designed to drive strong HPV-specific cellular immunity, especially CD8-positive T-cell responses against infected or transformed cells expressing high-risk HPV antigens, with potential additional humoral responses when VLP display is used. Publicly described programs indicate development by groups including GeoVax and academic collaborators for HPV-associated disease, including chronic HPV infection and HPV-related cancers such as head and neck cancer, but the queried name does not map cleanly to a single uniquely identified clinical product with a confirmed standardized composition, genotype coverage, or stage of development.

Other names

MVA-VLP-HPV vaccineMVA-VLP HPV vaccineMVA-HPV